4 Einträge gefunden

1. Carfilzomib 56 mg/m2 twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with bortezomib and dexamethasone (DVd): a matching-adjusted indirect treatment comparison

   1. Weisel, Katja
   2. Nooka, Ajay K
   3. Terpos, Evangelos
   4. Spencer, Andrew
   5. Goldschmidt, Hartmut
   6. Dirnberger, Franziska
   7. DeCosta, Lucy

   2022 - Forschungsinformationssystem des UKE
2. Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR

   1. Avet-Loiseau, Hervé
   2. San-Miguel, Jesus
   3. Casneuf, Tineke
   4. Iida, Shinsuke
   5. Lonial, Sagar
   6. Usmani, Saad Z
   7. Spencer, Andrew

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
3. Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies

   1. Mateos, Maria-Victoria
   2. Spencer, Andrew
   3. Nooka, Ajay K
   4. Pour, Ludek
   5. Weisel, Katja
   6. Cavo, Michele
   7. Laubach, Jacob P

   2020 - Forschungsinformationssystem des UKE
4. Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk

   1. Weisel, Katja
   2. Spencer, Andrew
   3. Lentzsch, Suzanne
   4. Avet-Loiseau, Hervé
   5. Mark, Tomer M
   6. Spicka, Ivan
   7. Masszi, Tamas

   2020 - Forschungsinformationssystem des UKE